IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies

• Published in: Annals of oncology Vol. 32; no. 6; pp. 736 - 745
• Main Authors: Barrios, D.M., Phillips, G.S., Geisler, A.N., Trelles, S.R., Markova, A., Noor, S.J., Quigley, E.A., Haliasos, H.C., Moy, A.P., Schram, A.M., Bromberg, J., Funt, S.A., Voss, M.H., Drilon, A., Hellmann, M.D., Comen, E.A., Narala, S., Patel, A.B., Wetzel, M., Jung, J.Y., Leung, D.Y.M., Lacouture, M.E.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2021
• Subjects: bullous pemphigoid; cutaneous adverse event; eczema; IgE; pruritus; urticaria; cutaneous adverse event; pruritus; eczema; bullous pemphigoid; IgE; urticaria

Immunoglobulin E (IgE) blockade with omalizumab has demonstrated clinical benefit in pruritus-associated dermatoses (e.g. atopic dermatitis, bullous pemphigoid, urticaria). In oncology, pruritus-associated cutaneous adverse events (paCAEs) are frequent with immune checkpoint inhibitors (CPIs) and ta...